INTRODUCTION AND OBJECTIVES: Detailed pathological information are necessary for follow-up analyses and new prediction tool development. Most institutional databases harbour a lack of either quantity or quality of such data. Expensive manpower needs to be manually invested for this purpose in daily clinical practice.
Natural language (NLP) processing presents immense potential to automate the information-gathering process in the field of urology. To propose and validate a novel tool to extract specific detailed pathological information from written health records that contain continuous, narrative text in an automated and precise way.
METHODS: Overall, 1500 postoperative narrative pathology reports of patients undergoing radical prostatectomy in 2015 were analyzed. Of these, 750 reports were randomly selected as training data and the remaining 750 reports were used as validation data. Using domain knowledge from clinical experts and Stanford treebank parser for German, rule based extraction algorithms were created for pathological staging, Gleason percentages, prostate dimension and laterality of the tumor by iterative review of misclassified reports until there are no longer any misclassified reports in the training data. Each number found in the reports was also verified by clinical experts.
RESULTS: By applying the developed NLP system on the validation data, we assed the accuracy of each information extracted. The NLP derived accuracy for pT-stage, pN-stage, Gleason percentage, prostate weight, prostate volume and laterality of the tumour were 100%, 100%, 100%,100% and 97%, respectively. CONCLUSIONS: We developed a novel NLP method that could extract detailed pathological information from a narrative, written pathological report with very high accuracy. This automated method can be implemented with the aim to greatly increase the efficiency and accessibility of research data in academic centers. 
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INTRODUCTION AND OBJECTIVES:
The incidence of metastatic prostate cancer has been increasing over the past decade. The landscape of treatment options has changed over this time period with the addition of new approaches to treatment, including the immunologic Sipuleucel-T (approved in 2010), and the chemotherapeutic agent Docetaxel, for which level 1 evidence for its first line use in hormonesensitive disease became available in 2015. To our knowledge, there is no previous large scale study investigating the trends in management over the last 10 years, nor baseline utilization of newer agents.
METHODS: The National Cancer Database (NCDB) was used to identify cases of metastatic prostate cancer, defined as cM1, between [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] [2014] . No changes to diagnostic criteria of metastatic disease were made during this time period. To minimize reporting bias, only hospitals contributing at least one case per year for the entire decade were included. Treatments codes were categorized and compared between years of diagnosis. Descriptive statistics were performed in Stata.
RESULTS: A total of 49,586 cases were included. The percentage of patients opting for surgical intervention as a care component (mostly palliative TURP) decreased over time, 12.7% in 2004 vs. 11% in 2014. Likewise, there has been a slight decrease in utilization of all forms of radiation therapy with 26.9% receiving radiotherapy in 2004 compared to 24.6% in 2014. The use of hormone therapy has increased 10% over the last decade (70.5% vs. 80.8%). Use of chemotherapy rose sharply over recent years but remains low. Single agent chemotherapy has increased from 3% in 2013 to 14% in 2014. Sipuleucel-T immunotherapy has seen modest use since its FDA approval in 2010, comprising <1% of patients in 2010, to 6.4% in 2014.
CONCLUSIONS: The treatment landscape for prostate cancer has changed dramatically over the last 10 years. Primary treatment plans are less likely to include radiation or surgical intervention, as one would expect given that local control is uncommonly recommended in the context of metastatic disease. The usage of hormone therapy continues to rise. Use of immunotherapy with Sipuleucel-T remained low at CoC accredited hospitals four years after its introduction. Possibly as a reflection of CHAARTED demonstrating benefit in high volume M1 disease, docetaxel use increased in 2014. Based on recent evidence supporting its first-line use for castrate sensitive M1 disease, we expect to see increased utilization going forward, with our study serving as a baseline for future comparison. . 197, No. 4S, Supplement, Sunday, May 14, 2017 analysis of a randomized, controlled phase II study of VPA in patients with non-metastatic biochemical progression of (BCR) CaP, and the utility of combining DHA with VPA in potentially reducing side effects. METHODS: Patients with non-metastatic BCR CaP were screened for eligibility and randomized into either observation or VPA (oral, twice daily) arms. Serum VPA and PSA levels were monitored biweekly and monthly. We also investigated methods of minimizing the side effects of VPA while maintaining efficacy.
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RESULTS: Treatment with VPA resulted in an increased PSA doubling time (PSADT) in patients from 4.02 to 40.67 months, while the PSADT in the control group stayed relatively unchanged at 6.34 to 6.95 months. However, the treatment group suffered from debilitating fatigue and lethargy at the dose required for effective treatment. As such we investigated options of reducing the VPA dose while maintaining efficacy. Both in vitro and in a mouse model we demonstrate that combining VPA with DHA has a greater efficacy. In the in vitro model we show that in the combination we can reduce the dose of VPA by half and still maintain similar efficacy. Also chronic treatment with the combination had a much greater effect on cell kill as opposed to acute treatment. Moreover, folic acid, another common supplement, enhances cell kill by the combination.
CONCLUSIONS: Based on our studies VPA could be used in combination with DHA, a supplement, to delay or even prevent the use of hormone therapy in prostate cancer patients with BCR. In addition, both clinicians and patients should be made aware of the effects of dietary supplements, as they can positively or potentially negatively affect the efficacy of certain drugs.
Source of Funding: None
PD37-09 IDENTIFICATION OF EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) SELECTIVE CYTOTOXIC COMPOUNDS IN PROSTATE CANCER CELLS
Marion Vanneste, Iowa City, IA; Qin Huang, Coralville, IA; Meng Wu, James Brown*, MIchael Henry, Iowa City, IA INTRODUCTION AND OBJECTIVES: Metastasis, the major driver of mortality in advanced prostate cancer, starts in the prostate when cancer cells start to invade the surrounding stromal tissue. This first step may involve EMT characterized by the loss of epithelial characteristics and the gain of mesenchymal features. Thus, developing therapeutic compounds specifically targeting this process may provide a therapeutic opportunity.
METHODS: In this study, we have developed a cell-based highthroughput screening protocol using the high content Operetta imaging platform to identify EMT cytotoxic compounds. A library of 2,640 compounds (Microsource) was screened on a co-culture of epithelial-like prostate cancer cells (PC3E GFP cells) and EMT-like prostate cancer cells (TEM 4-18 mCherry cells), both derived from the PC-3 cell line.
After 72h exposure to compounds, relative numbers of GFP-and mCherry-positive cells were quantitated using the Operetta system. Dose-response curves were established for each compound exhibiting a greater toxicity against EMT-like cells.
RESULTS: Among the compounds tested, monensin and salinomycin, both monovalent cation ionophores, exhibited a relatively greater toxicity against EMT-like cells. The highest potency and selectivity for the EMT-like cells was obtained with nigericin, another monovalent cation ionophore, followed by monensin and salinomycin. In addition to inducing apoptosis and a cell cycle arrest, monensin rapidly induced a swelling of golgi apparatus most likely resulting in a blockage of intracellular protein trafficking leading to cell death. In addition, we evaluated the toxicity of monensin in 24 cancer cell lines from different origins and classified them as resistant or sensitive. We analyzed publically available gene expression data and performed a Gene Set Enrichment Analysis to identify the gene sets differentially represented in the two groups. Supporting our hypothesis, the gene set involving EMT was enriched in the sensitive group.
CONCLUSIONS: In this study we identified monensin, salinomycin and nigericin as potent EMT-selective cytotoxic compounds. Understanding the mechanism-of-action of these compounds may lead to insight about the metastatic process and point to new therapeutic directions. We have used a genomics-based drug-repositioning approach to identify piperlongumine, a natural product constituent of the fruit of the Long pepper (Piper longum), as a potential therapeutic against NEPC. The efficacy of this drug was tested in the NEPC cell line model NCI-H660 and compared to several other PCa cell lines in a modified WST-1 assay. Pre-clinical testing in mouse xenograft models of NEPC was also undertaken. Finally, the ability of piperlongumine to inhibit p-STAT3 signaling and promote apoptosis in cell lines and extracted tumors were measured by western blot analyses.
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METHODS: PCa cell lines (LNCaP, 22Rv1, Du145, PC3, H660 and RWPE) were grown in complete media (RPM1 10%FBS, Advanced DMEM 5%FBS or Keratinocyte-SFM) and treated with piperlongumine for 3 or 7 days. IC50 values were generated from WST assay data using Prism6. Nude mice (n¼5) were injected with 1.5x106 H660 cells on each flank, and intraperitoneally administered with either 2.5mg/kg piperlongumine (n¼3) or DMSO (n¼2) daily for 3 weeks after tumors formed 200mm3 in volume. Tumor volume was measured daily with calipers. Western blot analyses were performed on protein lysates extracted from tumors and PCa cells treated with 0-10 mM of drug.
RESULTS: Piperlongumine was highly effective in inhibiting the growth of H660 cells (IC50 ¼ 0.4 mM) compared to LNCaP, 22Rv1, Du145, PC3, and RWPE cells. On average, the growth rate of untreated tumors was 2.7 times greater than those treated was piperlongumine. Treated H660 cells exhibited significant inhibition of p-STAT3 and increases in cPARP1 levels while other cell lines displayed little to no fluctuation.
CONCLUSIONS: Using drug-repositioning approaches we have identified a lead compound that inhibits the growth of the highly drug-resistant NEPC cell line NCI-H660. Remarkably, piperlongumine happens to be a water-soluble plant product with no known side effects.
